Trial Profile
ONO 5334 sustained-release efficacy and pharmacokinetics when administered as single doses of 50, 100 or 300mg in postmenopausal women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs ONO 5334 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 14 Oct 2011 New trial record
- 20 Sep 2011 Results presented for the first part of the study at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.